StockNews.AI
PEPG
StockNews.AI
14 days

PepGen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG

1. PepGen Inc. faces a class action lawsuit over alleged securities fraud. 2. Allegations include misleading safety and efficacy of PGN-EDO51. 3. Investors may recover losses without upfront costs or fees. 4. Deadline for lead plaintiff application is August 8, 2025. 5. Levi & Korsinsky has a history of winning securities litigation.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit suggests significant regulatory issues with PEPG's lead product, jeopardizing credibility and future sales, similar to past biotech cases where legal allegations negatively impacted stock prices dramatically.

How important is it?

Given the centrality of PGN-EDO51 to PEPG’s business model, any legal challenges can severely disrupt its market performance and investor sentiments.

Why Long Term?

The effects of legal actions like this can delay product launches and reduce investor confidence over a prolonged period, as seen in similar biotechnology firms that faced regulatory scrutiny.

Related Companies

PFEMRNABMY
, /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PepGen Inc. ("PepGen Inc." or the "Company") (NASDAQ: PEPG) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PepGen Inc. investors who were adversely affected by alleged securities fraud between March 7, 2024 and March 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/pepgen-inc-lawsuit-submission-form?prid=159008&wire=4  PEPG investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in PepGen Inc. during the relevant time frame, you have until August 8, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News